Epigenetic regulation of SST
DNA methylation
H3K27me3
H3K9ac
SI-NET
epigenetic
histone modifications
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
11
03
2023
accepted:
11
04
2023
medline:
26
5
2023
pubmed:
24
5
2023
entrez:
24
5
2023
Statut:
epublish
Résumé
Somatostatin receptor type 2 (SST Tissue samples from 16 patients diagnosed with SI-NETs and undergoing surgical resection of the primary tumor at Erasmus MC Rotterdam were analysed for SST The SI-NET samples had high SST SI-NETs have lower SST
Sections du résumé
Background
Somatostatin receptor type 2 (SST
Methods
Tissue samples from 16 patients diagnosed with SI-NETs and undergoing surgical resection of the primary tumor at Erasmus MC Rotterdam were analysed for SST
Results
The SI-NET samples had high SST
Conclusion
SI-NETs have lower SST
Identifiants
pubmed: 37223009
doi: 10.3389/fendo.2023.1184436
pmc: PMC10200989
doi:
Substances chimiques
Histones
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1184436Informations de copyright
Copyright © 2023 Klomp, Refardt, van Koetsveld, Campana, Dalm, Dogan, van Velthuysen, Feelders, de Herder, Hofland and Hofland.
Déclaration de conflit d'intérêts
Author RF received research support from Ipsen, Strongbridge and Corcept as well as speaker fees from HRA Pharma, Novartis, Ipsen. Author WH received research support from AAA-Novartis, speaker fees from Ipsen and AAA-Novartis and is on the advisory board of AAA. Author JH received speaker fees from Ipsen and is on the advisory board of Novartis. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Endocrinology. 2008 Jun;149(6):3137-47
pubmed: 18325993
Cancers (Basel). 2019 Jun 03;11(6):
pubmed: 31163616
Endocr Relat Cancer. 2017 Sep;24(9):R315-R334
pubmed: 28710117
Rev Endocr Metab Disord. 2021 Sep;22(3):581-594
pubmed: 32495250
Eur J Endocrinol. 2022 Jul 21;187(3):399-411
pubmed: 35895707
Clin Transl Med. 2022 Jul;12(7):e957
pubmed: 35866246
Oncotarget. 2016 May 19;9(19):14791-14802
pubmed: 29599907
Ann Endocrinol (Paris). 2019 Jun;80(3):153-158
pubmed: 31072588
Clin Cancer Res. 2016 Jan 1;22(1):250-8
pubmed: 26169971
Allergy Asthma Clin Immunol. 2018 May 23;14:39
pubmed: 29796022
Cancers (Basel). 2021 Sep 29;13(19):
pubmed: 34638389
Hum Pathol. 2017 Jul;65:41-52
pubmed: 28235630
Int J Mol Sci. 2018 Oct 12;19(10):
pubmed: 30321986
Mod Pathol. 2007 Jul;20(7):802-10
pubmed: 17483816
Hum Pathol. 2010 Feb;41(2):181-9
pubmed: 19896696
J Nucl Med. 2016 Nov;57(11):1805-1810
pubmed: 27363833
Surgery. 2020 Jan;167(1):189-196
pubmed: 31629542
J Nucl Med. 2019 Sep;60(9):1240-1246
pubmed: 30796167
Cancer Biother Radiopharm. 2021 Oct;36(8):632-641
pubmed: 34252288
Epigenetics. 2014 Jul;9(7):987-97
pubmed: 24762809
Endocrine. 2006 Dec;30(3):299-306
pubmed: 17526942
Nature. 2019 Nov;575(7781):210-216
pubmed: 31645765
Eur J Cancer. 2022 Nov;176:110-120
pubmed: 36208569
Endocr Relat Cancer. 2020 Nov;27(11):615-624
pubmed: 33032265
Endocr Connect. 2019 Jul;8(7):906-922
pubmed: 31189127
Rev Endocr Metab Disord. 2021 Sep;22(3):495-510
pubmed: 33085037